JNJ-39393406
- Generic Name
- JNJ-39393406
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18F2N6O3
- CAS Number
- 953428-73-4
- Unique Ingredient Identifier
- T930SOU82P
- Background
JNJ-39393406 has been used in trials studying the treatment and basic science of DEPRESSION, Schizophrenia, Smoking Cessation, Cognition Disorders, and Alzheimer's Disease.
The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2020-05-22
- Lead Sponsor
- Tangent Data
- Target Recruit Count
- 80
- Registration Number
- NCT02677207
- Locations
- 🇷🇴
Hospital of Psychiatry and Neurology, Brasov, Romania
🇲🇩Clinical Psychiatric Hospital, Codru, Moldova, Republic of
🇷🇴S.C. Stefi-Dent Srl, Botosani, Romania
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39393406 in Healthy Participants
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2014-01-24
- Target Recruit Count
- 88
- Registration Number
- NCT02023255
A Pharmacokinetic Study to Characterize JNJ-39393406 in the Cerebrospinal Fluid of Healthy Volunteers
- First Posted Date
- 2012-03-16
- Last Posted Date
- 2013-07-24
- Target Recruit Count
- 12
- Registration Number
- NCT01556217
The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients
Phase 1
Terminated
- Conditions
- SchizophreniaAlzheimer's DiseaseCognition Disorders
- Interventions
- Drug: placebo
- First Posted Date
- 2010-06-04
- Last Posted Date
- 2012-11-08
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 47
- Registration Number
- NCT01137799
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath